VBIO

Valion Bio, Inc.

$0.53

-2.35%

SectorHealthcareIndustryBiotechnologyCountryUnited States

Overview AI Brief ChartChart & Performance Financials ExposureRevenue Exposure FilingsFilings & Red Flags ScoresScores & Valuation News Analysts InsidersInsiders & Short Interest Ownership

Valion Bio, Inc. operates as a late-stage biopharmaceutical company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company's pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically optimized variant of Entolimod for chronic applications, such as immunosenescence. In addition, it offers CDMO services. The company was formerly known as Tivic Health Systems, Inc. and changed its name to Valion Bio, Inc. in April 2026. The company was incorporated in 2016 and is based in San Antonio, Texas.

Source: Yahoo Finance

Market Cap$1.1M

Dividend Yield0.00%

Beta1.33

AI summary

Price & performance

1M-45.3%

3M-90.8%

YTD-96.7%

1Y-98.4%

52-week range—

Beta1.33

Full chart and returns against a benchmark

Q-Score

9/ 100

Quality against peers; 50 is the peer median.

Growth—

Risk21

Performance22

Valuation—

Profitability4

Leverage45

Sentiment—

Every score and metric

News sentiment

Open News

Latest results · FY 2025

Revenue—

Net income-$8.9M

Net margin—

Historical fundamentals

Red flags in filings

3active red flags

Going-concern doubtMar 30, 2026

Material weakness in controlsMar 30, 2026

Exchange listing noticeMar 20, 2026

Filings, findings and the timeline

Revenue exposure

0%of revenue from outside the US

United States100%

Largest customer18%

Regions, segments, customers and suppliers

Valuation

VBIOIndustryP/E—89.69P/S—11.88EV/EBITDA—67.10P/B0.276.22PEG—4.02

Dividend yield0.00%

Every valuation metric

Historical Fundamentals

Revenue

Net Income

Net Margin

Showing the last 4 periods. Pro adds the full annual and quarterly history and 20+ more metrics to chart.

Latest Results

The latest fiscal year and quarter, each against the same period a year earlier, from SEC filings.

Metric	FY 2025	vs a year before	Q2 2026	vs a year before
Net Income	-$8.9M	—	-$7.1M	—

Q-Scores

OverallCombines the categories below, except Sentiment

Industry 579

Risk

Industry 5521

Performance

Industry 6622

Profitability

Industry 474

Leverage

Industry 6845

Key Metrics

Fundamentals: trailing twelve months to Jun 2026, from the latest 10-K and 10-Qs.

Market Beta (5-factor)

IM 0.72SM 0.780.69

Market Cap

1.1M

Dividend Yield

IM 0.00%SM 0.00%0.00%

Volume

IM 693.1KSM 741.7K2M

Industry Market Share

0.00%

Sector Market Share

0.00%

IM industry median · SM sector median: the typical company the value is compared with. The /100 is its score against those peers.

Comparable Companies

The companies closest in size in Biotechnology (filled from its sector when there are few), with the median and rank across all 571 in the industry.

Company	Market cap	P/S	P/B	FCF yield	Op. margin	ROE	Debt/equity
VBIOValion Bio, Inc.	$1.1M	—	0.3	—	—	-441.6%	0.0
GOVXGeoVax Labs, Inc.	$1.1M	—	0.6	—	—	—	0.0
BBLGBone Biologics Corporation	$1.2M	—	0.2	-222.2%	—	-47.8%	0.0
ARTLArtelo Biosciences, Inc.	$1.2M	—	0.2	—	—	-253.6%	0.0
MTNBMatinas BioPharma Holdings, Inc.	$1.2M	—	0.7	-532.9%	—	-371.7%	0.0
SCNIScinai Immunotherapeutics Ltd.	$1.3M	1.0	0.2	-474.7%	-575.3%	-102.5%	0.0
BDRXBiodexa Pharmaceuticals Plc	$1.3M	—	0.1	-584.1%	—	-56.0%	0.0
LABTLakewood-Amedex Biotherapeutics, Inc.	$985.8K	—	0.2	-353.6%	—	-169.6%	0.0
ELABPMGC Holdings Inc.	$1.4M	2.3	0.1	-632.2%	—	-80.6%	0.0
Industry median		7.7	2.2	-22.3%	-76.9%	-60.8%	0.0
VBIO percentile		—	5th	—	—	4th	39th